...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Lead identification of conformationally restricted beta-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
【24h】

Lead identification of conformationally restricted beta-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.

机译:构象受限的β-内酰胺型康维他汀类似物的前导鉴定:合成,抗增殖活性和微管蛋白靶向作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The synthesis and study of the structure-activity relationships of a series of rigid analogues of combretastatin A-4 are described which contain the 1,4-diaryl-2-azetidinone (beta-lactam) ring system in place of the usual ethylene bridge present in the natural combretastatin stilbene products. The 1,4-diaryl-2-azetidinones are unsubstituted at C-3, or contain methyl substituent(s) at C-3. The most potent compounds 12d and 12e display antiproliferative activity at nanomolar concentrations when evaluated against the MCF-7 and MDA-MB-231 human breast carcinoma cell lines. 12d exerts antimitotic effects through an inhibition of tubulin polymerisation and subsequent G2/M arrest of the cell cycle in human MDA-MB-231 breast cancer cells, with similar activity to that of CA-4. These novel beta-lactam compounds are identified as potentially useful scaffolds for the further development of antitumour agents which target tubulin.
机译:描述了一系列康美他汀A-4刚性类似物的合成和结构-活性关系的研究,这些类似物包含1,4-二芳基-2-氮杂环丁酮(β-内酰胺)环系统来代替通常的乙烯桥在天然康美他汀二苯乙烯产品中。 1,4-二芳基-2-氮杂环丁酮在C-3处未被取代,或在C-3处含有一个或多个甲基取代基。当针对MCF-7和MDA-MB-231人乳腺癌细胞系进行评估时,最有效的化合物12d和12e在纳摩尔浓度下显示出抗增殖活性。 12d通过抑制人MDA-MB-231乳腺癌细胞中的微管蛋白聚合和随后的G2 / M细胞周期阻滞而发挥抗有丝分裂作用,其活性与CA-4相似。这些新的β-内酰胺化合物被认为是潜在的有用的支架,用于进一步开发靶向微管蛋白的抗肿瘤剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号